Achilles therapeutics announces strategic update

–achilles to discontinue development of til-based cnet therapy– –cash position of $95.1 million as of june 30, 2024– –bofa securities engaged to provide strategic financial advice–         london, sept. 19, 2024 (globe newswire) -- achilles therapeutics plc (nasdaq: achl) today announced the discontinuation of its til-based cnet program and closure of the phase i/iia chiron and thetis clinical trials.
ACHL Ratings Summary
ACHL Quant Ranking